Literature DB >> 33570724

High thyroglobulin and negative whole-body scan: no long-term benefit of empiric radioiodine therapy.

Mariana Yoshii Tramontin1, Gabriela Maia Nobre2, Marcia Lopes3, Michel Pontes Carneiro3,4, Paulo Alonso Garcia Alves2, Fernanda Accioly de Andrade2, Fernanda Vaisman2, Rossana Corbo2,3, Daniel Bulzico2,3.   

Abstract

PURPOSE: Around 10-27% of patients will present elevated thyroglobulin (Tg) levels and negative diagnostic whole-body scan (dxWBS) during differentiated thyroid cancer (DTC) follow-up. Empiric radioactive iodine (RAI) therapy in this context is controversial due to the lack of good quality studies in the context. The main purpose of this study is to compare long-term response to therapy status and overall survival between empiric RAI treated and untreated DTC patients.
METHODS: A retrospective study comparing differentiated thyroid cancer patients with negative diagnostic whole-body scan and elevated thyroglobulin levels submitted or not to empiric radioactive iodine therapy in a thyroid cancer referral center. The main outcome measures were ATA Response to Therapy Stratification at 6-12 months after RAI ablative dose, at 6-18 months after negative dxWBS and last follow-up visits.
RESULTS: Overall, 120 DTC patients with stimulated Tg >10 ng/ml and negative dxWBS were included in this study. Overall, 53 patients were submitted to empiric RAI and 67 were in the control group. No difference was observed in ATA Response to Therapy Stratification after RAI ablation or at the end of follow-up between groups. Also, no difference was found in terms of Tg changes response. After more than 10 years of follow-up, 17 patients died (13 from treated and 4 from untreated group).
CONCLUSIONS: Empiric RAI treatment was not associated with better long-term ATA response to therapy status or overall survival.

Entities:  

Keywords:  Differentiated thyroid cancer; Iodine-131; Radioiodine therapy; Thyroid cancer; Whole-body scan

Year:  2021        PMID: 33570724     DOI: 10.1007/s12020-021-02647-8

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  2 in total

1.  Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin.

Authors:  K M van Tol; P L Jager; E G E de Vries; D A Piers; H M Boezen; W J Sluiter; R P F Dullaart; T P Links
Journal:  Eur J Endocrinol       Date:  2003-06       Impact factor: 6.664

2.  Clinical outcomes of low and intermediate risk differentiated thyroid cancer patients treated with 30mCi for ablation or without radioactive iodine therapy.

Authors:  Shirlei Kugler Aiçar Súss; Cleo Otaviano Mesa; Gisah Amaral de Carvalho; Fabíola Yukiko Miasaki; Carolina Perez Chaves; Dominique Cochat Fuser; Rossana Corbo; Denise Momesso; Daniel A Bulzico; Hans Graf; Fernanda Vaisman
Journal:  Arch Endocrinol Metab       Date:  2018-04-05       Impact factor: 2.309

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.